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ABSTRACT: Dendritic cells (DCs) are armed with a multitude of
Pattern Recognition Receptors (PRRs) to recognize pathogens and
initiate pathogen-tailored T cell responses. In these responses, the
maturation of DCs is key, as well as the production of cytokines
that help to accomplish T cell responses. DC-SIGN is a frequently
exploited PRR that can eﬀectively be targeted with mannosylated
antigens to enhance the induction of antigen-speciﬁc T cells. The
natural O-mannosidic linkage is susceptible to enzymatic
degradation, and its chemical sensitivity complicates the synthesis
of mannosylated antigens. For this reason, (oligo)mannosides are
generally introduced in a late stage of the antigen synthesis,
requiring orthogonal conjugation handles for their attachment. To
increase the stability of the mannosides and streamline the
synthesis of mannosylated peptide antigens, we here describe the development of an acid-stable C-mannosyl lysine, which allows for
the inline introduction of mannosides during solid-phase peptide synthesis (SPPS). The developed amino acid has been successfully
used for the assembly of both small ligands and peptide antigen conjugates comprising an epitope of the gp100 melanoma-associated
antigen and a TLR7 agonist for DC activation. The ligands showed similar internalization capacities and binding aﬃnities as the O-
mannosyl analogs. Moreover, the antigen conjugates were capable of inducing maturation, stimulating the secretion of pro-
inﬂammatory cytokines, and providing enhanced gp100 presentation to CD8+ and CD4+ T cells, similar to their O-mannosyl
counterparts. Our results demonstrate that the C-mannose lysine is a valuable building block for the generation of anticancer
peptide-conjugate vaccine modalities.
Immunotherapy for cancer is gaining momentum. More andmore therapies have reached the clinic or are in advanced
clinical trials, including immune checkpoint blocking (ICB)
antibodies, chimeric antigen receptor T cells (CAR T cells),
adoptive cell transfer (ACT), and dendritic cell (DC)
vaccination.1−4 DC-based strategies rely on the role of
dendritic cells as key initiators of the adaptive immune system
that are crucial in the induction of memory responses. Via
antigen capture and processing, DCs can present peptides to
naiv̈e T lymphocytes and skew their diﬀerentiation end points,
and by exposing DCs to synthetic tumor (neo-)antigens, the
immune response can be directed toward speciﬁc cancer-
associated antigens. Although animal models have demon-
strated promising results for peptide-based vaccine strategies,
human trials often result in minimal tumor regression and only
partial eﬀectiveness.5,6 Vaccine eﬃcacy may be improved by
the incorporation of adjuvants that can target Pattern
Recognition Receptors (PRRs), which can induce DC
maturation and improve antigen processing.7 Toll-Like
Receptors (TLRs) are a family of PRRs, of which members
have been successfully targeted with covalent adjuvant-antigen
conjugates,8−12 to induce DC maturation and improve antigen
processing and presentation.13,14 Another family of PRRs that
has frequently been exploited as an endocytic receptor to
facilitate antigen cross-presentation is the C-type Lectin
Receptors (CLRs). This family of PRRs recognizes carbohy-
drate patterns and is an essential determinant in discerning
host from foreign antigens. An often studied receptor is DC-
SIGN (CD209), a CLR present on DCs that internalizes
carbohydrate modiﬁed antigens for cross-presentation to T
cells. DC-SIGN recognizes mannose and Lewis-type carbohy-
drate moieties on a wide variety of pathogens and is often
targeted to activate speciﬁc signaling and tailor the immune
response.15 DC-SIGN can also act as a scavenger receptor that
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can induce receptor-mediated endocytosis. Due to its tetramic
structure, a multivalent presentation of its ligand enhances the
avidity for DC-SIGN. Thus, while the aﬃnity for a single
monomannoside ligand is low, targeting mannosylated
constructs can be markedly increased by the multivalent
presentation of the monosaccharides on a polyvalent core or
carrier platform such as dendrimers, liposomes, or nano-
particles.16−18 Vaccination with mannosylated antigens in mice
has demonstrated improved cytotoxic lymphocyte responses,
stronger Th1 and Th2 responses, and increased antibody
responses.19 The addition of an adjuvant can further boost the
generated immune response of mannosylated conjugates. For
example, the conjugation of multivalent mannosides and TLR7
adjuvants to an antigen via a self-immolative linker resulted in
a more robust and higher-quality humoral and cellular immune
response in mice.20
In earlier work, we have also demonstrated the signiﬁcance
of antigen mannosylation.21 We systematically increased the
number of well-deﬁned mono-, di-, and trimannosides on a
peptide backbone to evaluate the eﬀect of multivalent
presentation of DC-SIGN ligands on the peptide antigens.
We could also extend the conjugates with a secondary
adjuvant. Using this strategy, we generated precisely deﬁned
trifunctional conjugates (CLR-antigen-TLR), which eﬀectively
targeted DC-SIGN.21 This approach, however, required the
conjugation of O-mannosides via a Cu(I) catalyzed azide−
alkyne cycloaddition (CuAAC), which involved an additional
puriﬁcation step and limits the number of available orthogonal
handles that can be incorporated into the conjugates.
Furthermore, O-mannosides may be enzymatically cleaved,
rendering them less suitable for DC-SIGN targeting.16,22,23
Therefore, we here report the design and synthesis of a C-
mannose functionalized lysine building block (1, Scheme 1).
This C-mannoside lacks the exocyclic anomeric oxygen to
render the glycosidic linkage resistant to the acidic conditions
necessary for standard automated solid phase peptide synthesis
(SPPS). In addition, the C-glycoside is resistant to enzymatic
hydrolysis. By attachment to an Fmoc-protected amino acid
building block, the mannoside can be incorporated via “inline”
synthetic methodology, obviating postsynthesis conjugation
steps and preventing the use of an azide−alkyne click reaction.
The C-mannoside building block has been used to generate
peptide-antigen conjugates, carrying one or six mannosides, in
addition to a synthetic TLR7 ligand. The generated constructs
have been evaluated, in a side by side comparison to the
corresponding O-mannoside clusters, for binding aﬃnity,
uptake, and antigen presentation capacity, revealing that C-
mannosides can eﬀectively be used to replace their more labile
O counterparts in covalent antigen conjugates.
■ RESULTS AND DISCUSSION
Synthesis of the C-Mannoside Lysine Building Block.
The synthesis of the key SPPS-ready mannosylated Fmoc
amino acid is achieved in 11 steps and is shown in Scheme 1.
The crucial step in the synthesis of 1 is the introduction of the
α-C-glycosidic bond. On the basis of previously reported work
by Girard et al.,24 the anomeric allyl was introduced via a
Hosomi−Sakurai reaction using allyltrimethylsilane (allyl-
TMS). The synthesis starts from methyl 2,3,4,6-tetra-O-
benzyl-α-D-mannopyranoside 3, obtained by benzylation of
Scheme 1. Synthesis of C-Mannoside Lysine 1a
aReagents and conditions: (a) NaH, BnBr, TBAI, DMF, 78%; (b) allylTMS, TMSOTf, ACN, 73%; (c) either (i) BCl3, DCM and (ii) Ac2O,
pyridine 95% or (i) Li, naphthalene, THF, −20 °C and (ii) Ac2O, pyridine, 54%; (d, i) NaOMe, MeOH, (ii) NaH, PMBCl, TBAI, DMF, 69%; (e)
methyl acrylate, Grubbs second gen. catalyst, DCM, 73%; (f) RuCl3, NaBH4, DCE/MeOH, 93%; (g) KOH, THF/H2O, qnt.; (h) 11, HCTU,
DIPEA, DMF, 99%; (i) LiOH, H2O2, THF/H2O/t-BuOH, 79%.
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methyl α-D-mannopyranoside 2. [The use of per-acetylated
mannosyl donors has previously been shown to lead to
anomeric mixtures, indicating that neighboring group partic-
ipation falls short in eﬀecting stereoselective C-glycosylation
reactions.21−25] The allyl group was introduced by treatment
of the methyl mannoside with allyltrimethyl silane and
trimethylsilyl triﬂate in acetonitrile to provide C-mannoside
4. This reaction proceeded with high stereoselectivity and was
complete within an hour when assisted by ultrasound
irradiation.25 Selective removal of the benzyl ethers in the
presence of the allyl functionality was initially eﬀected using
either BCl3 or a Birch reduction in liquid ammonia.
26
However, both reactions proved diﬃcult to scale up, and we
therefore switched to the use of a single electron reduction
using lithium naphthalenide in THF. This reaction could be
run at 80 mmol scale, to provide the desired tetra-ol, which
was acetylated to ease puriﬁcation, delivering 5 in 54% yield.
After the installation of four PMB ethers, the anomeric allyl
appendage was elongated through a cross-metathesis with
methyl acrylate to aﬀord α,β-unsaturated ester 7. The
reduction of the double bond in this product with RuCl3 in
the presence of NaBH4 and MeOH
27 was followed by
saponiﬁcation of the resulting ester 8 to obtain carboxylic
acid 9. Fully protected C-mannosyl lysine 12 was obtained by
Figure 1. Binding of the C-mannoside clusters to DC-SIGN. (A) Structure of the mono-, di-, tri-, or hexavalent O-mannoside clusters, with and
without biotin. (B) Schematic representation of the binding, internalization, and endosomal routing assays. (C) Binding of the biotinylated clusters
to moDC DC-SIGN as measured by ﬂow cytometry (left panel, eight donors) and to moDC with blocked DC-SIGN (right panel). Polyacrylamide
decorated with monomannosides or LeY antigens were used as positive controls. Paired Student’s t test error: *p < 0.05; **p < 0.001. (D) DC-
SIGN-mediated internalization of the clusters was measured by ﬂow cytometry. One donor is depicted as a representative of four individuals. (E)
The routing of the clusters to the endosomes/lysosomes as measured by ﬂow cytometry and normalized to a negative control. One donor is
depicted as representative of three individuals.
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coupling of carboxylic acid 9 with the methyl ester of Nα-Fmoc
protected lysine 11, using HCTU as condensation agent.
Selective hydrolysis of the ester in the presence of the Fmoc
group was achieved with LiOOH,28,29 which is more
nucleophilic but less basic than LiOH,30 resulting in the
isolation of key building block 1 in 79% yield. Altogether,
SPPS-compatible C-mannosyl 1 was synthesized in 20% yield
over 11 steps.
Synthesis of the Mannoside Clusters. Our previous
work has described the synthesis of the O-mannoside clusters21
and resulted in monovalent- (24), bivalent- (25), trivalent-
(26), and hexavalent (27) O-mannoside clusters. Biotinylation
of these compounds resulted in biotinylated O-mannoside
clusters 28, 29, 30, and 31, respectively (Figure 1A). To enable
a direct comparison to these clusters, we here generated
clusters containing one, two, three, or six copies of the C-
mannosyl through an SPPS approach (Scheme 2). Using
Tentagel S RAM amide resin, Fmoc-Lys(Boc)-OH and Fmoc-
Gly-OH were introduced successively, followed by elongation
with C-mannosyl 1 using a standard Fmoc protocol and
HCTU as the condensation agent. Building block 1 was
introduced manually, using only a small excess of the amino
acid and prolonged coupling times (2 equiv, overnight) to
prevent the use of a large excess of 1. After completion of the
sequence, the N-termini were capped with acetyl groups,
resulting in immobilized peptides 12−15. Subjecting resins
12−15 to a cleavage cocktail of TFA/TIS/H2O (190/5/5, v/
v/v) successfully removed the Boc and PMB ethers, and the
peptide clusters were isolated after RP-HPLC puriﬁcation to
obtain monovalent (16), bivalent (17), trivalent (18), and
hexavalent (19) clusters in 7%, 14%, 6%, and 2% yield,
respectively (Scheme 2, R = R1). Further functionalization via
the introduction of a biotin handle was achieved by reacting
the primary amine of the C-terminal lysine with a biotin-N-
hydroxysuccinimide (NHS) ester. This resulted in biotinylated
mannoside clusters 20−23 (Scheme 2, R = R2).
Binding of the C-Mannoside Clusters to moDCs. With
the biotinylated constructs in hand, the eﬀect of the O to CH2
modiﬁcation was evaluated by studying the binding, internal-
ization, and endosomal routing upon DC-SIGN engagement of
the C-mannoside clusters and their O-mannoside equivalents
28−31 (Figure 1A,B).21 The binding of the clusters to cellular
membrane DC-SIGN was evaluated using DC-SIGN express-
ing monocyte-derived DCs (moDCs; Figure 1C, also see
Supporting Information, Figure SI.1A). The assay was
performed at a temperature of 4 °C to prevent the
internalization of DC-SIGN from the cell membrane surface.
The cells were incubated with the biotinylated clusters for 30
min, after which unbound clusters were washed away.
Treatment of the cells with ﬂuorophore-labeled streptavidin
allowed quantiﬁcation of binding by ﬂow cytometry. An
increase in binding of bivalent C-mannoside 21, trivalent O-
mannoside 30 and C-mannoside 22, and hexavalent O-
mannoside 31 and C-mannoside 23 was seen when compared
to the unstimulated control. Compared to a mannosylated
polyacrylamide control, all compounds showed better binding,
with the exception of mono-O-mannoside 28. A clear valency-
dependent increase in binding was seen within each of the O-
and C-mannoside sets. These results are in line with our
previous study, in which we compared the monomannoside
Scheme 2. Synthesis of C-Mannoside Clustersa
aReagents and conditions: (a) Fmoc-SPPS (1, HCTU, DIPEA, DMF); (b) TFA, TIS, H2O, (octanethiol, phenol; 16, 7.0%; 17, 14%; 18, 6.0%; 19,
2.1%); (c) BiotinOSu, DIPEA, DMSO (20, 94%; 21, 72%; 22, 99%; 23, 80%).
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Scheme 3. Synthesis of C- and O-Mannoside−gp100−TLR7 Agonist Conjugatesa
aReagents and conditions: (a) Fmoc-SPPS (1, HCTU, DIPEA, DMF); (b) Fmoc-SPPS (Fmoc-AEEA-OH or 32, HCTU, DIPEA, DMF); (c, i)
Ac2O, DIPEA, DMF; (ii) AcOH, TFE, DCM; (iii) Fmoc-SPPS (Fmoc-AEEA-OH or 32, HCTU, DIPEA, DMF); (d) TFA, TIS, H2O, octanethiol,
phenol (39, 2.60% over 36 couplings; 40, 1.30% over 41 couplings; 41, 2.10% over 36 couplings; 42, 0.60% over 41 couplings); (e) Fmoc-SPPS,
see ref 21; (f) pent-4-ynoic acid succinimidyl ester, DIPEA, DMSO (43, 62%; 44, 66%); (g) CuI, THPTA, DIPEA, H2O, DMSO (46, 34%; 47,
29%).
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clusters to clusters built up from more complex di- and
trimannosides.21 For all clusters, higher valency led to higher
binding aﬃninty. Binding of the hexavalent monomannoside
cluster was comparable to the binding of the higher valent di-
and trimannosides. Blocking of the DC-SIGN receptor
eﬀectively diminished the binding, although low residual
binding with a similar valency-dependent increase remained
(see SI, Figure SI.1B). The residual binding suggests cluster
recognition of other mannose-binding receptors on DCs, such
as the mannose receptor.31
We next selected the mono- and hexavalent O- and C-
mannoside clusters to assess their internalization. The
assessment of cluster internalization was executed at 4 °C,
similar to the binding assay. To this end, the cells were
incubated for 60 min to saturate the immobilized DC-SIGN
receptors at the cell surface, followed by the removal of
unbound clusters. Resuspension of the samples in warm (37
°C) medium initiated internalization. At the indicated time
points, samples were taken and immediately put on ice. The
signal loss of the membrane was measured through ﬂow
cytometry upon treatment with a ﬂuorophore-conjugated
streptavidin. To exclude cluster-DC-SIGN dissociation, we
additionally gently ﬁxed the cells with 1% paraformaldehyde
for permanent immobilization of DC-SIGN at the membrane.
No dissociation of the mannosylated clusters from DC-SIGN
on ﬁxed cells was measured (see SI, Figure SI.1C), indicating
that the ligands are internalized upon DC-SIGN binding.
Internalization (>50%) of the hexavalent cluster 23 was seen
after 5 min (Figure 1D). The complementary O-mannoside
cluster (31) accomplished the same level of internalization
after 15 min. Uptake of the monovalent clusters occurred at a
slower rate, requiring 30 min for internalization of approx-
imately 50% of both the O- and C-mannose clusters (28, 20).
The relative internalization eﬃciency seems to mirror the
binding proﬁles seen in Figure 1C.
Mono- and hexavalent cluster traﬃcking to the endosomes
was further studied using pHrodo Red. This dye acts as a pH-
sensitive sensor, as the ﬂuorescence is considerably increased
in acidic environments, while it is quenched in the neutral
extracellular environment. Prior to moDC stimulation, the
biotinylated mannoside clusters were treated with the avidin-
conjugated ﬂuorophore (2:1). The precomplexed clusters were
subsequently added to the moDCs at 37 °C, continued by
sample collection at each time point. The cells were washed
and gently ﬁxed, and ﬂuorescence was subsequently measured
by ﬂow cytometry. After 30 min, a 2-fold increase was visible in
the ﬂuorescence of the hexavalent O- and C-mannoside
clusters (Figure 1E). On the other hand, the ﬂuorescence of
both monovalent clusters (28 and 20) was increased 2.5-fold
at 30 min, suggesting higher endosomal ligand concentrations.
Although the C-mannosides resembled the O-mannoside
clusters, the deviation between mono- and hexavalent
presentation is surprising. In the previous binding and
internalization assays, the hexavalent clusters 31 and 23 were
superior to monovalent mannoside presentation. The
increased MFI of the monovalent over the hexavalent clusters
at 30 min could indicate faster endolysosomal traﬃcking of the
smaller clusters, as the emitted ﬂuorescence by the dye is
higher with lower pH.32,33 Moreover, the mannosylated
clusters were precomplexed with the pHrodo dye into a larger
particle, possibly contributing to the altered endocytosis.34
Altogether these results indicate that the C-mannoside clusters
20 and 23 were able to convincingly resemble the DC-SIGN
binding16 and internalization proﬁles of the O-mannoside
equivalents, encouraging the implementation of C-mannosy-
lated antigen conjugates.
Synthesis of Mannosylated gp100 Conjugates.
Melanoma derived from transformed pigment-carrying mela-
nocytes is a highly lethal cancer, and this malignancy is
considered one of the most immunogenic cancer types.35 We
therefore selected the melanoma-associated antigen gp100 as
our vaccine target, and we introduced C-terminal mannoside
clusters and a secondary TLR ligand to generate self-adjuvating
peptide antigen vaccine conjugates.36 Endosomal TLR7 was
selected as a PRR target because we reasoned that the use of a
cell surface PRR targeting PAMP would lead to competition
for binding with DC-SIGN on the outside of the DC surface
membrane. Furthermore, DC-SIGN-mediated endocytosis
should deliver the conjugates to the endosomes, where it will
encounter the TLR7 receptor. The target gp100 peptide
antigen combines the CD4+ T cell binding epitope
gp100280−288 and CD8
+ T cell binding epitope gp10044−59.
Multiple conjugates were synthesized bearing the TLR7
agonist either on the N or C terminus and carrying either
one or six mannosides, to study the eﬀect of these
modiﬁcations on antigen presentation.
The SPPS of the conjugates started with the introduction of
a monomethoxytrityl (Mmt) functionalized Fmoc-Lys-OH on
Tentagel S RAM amide resin (Scheme 3). Both termini of the
antigen sequence were extended with four naturally occurring
amino acids to act as spacers between the antigens, the
mannoside cluster, and the TLR7 ligand. The Cys60 in the N-
terminal spacer was replaced with an isosteric α-amino-butyric
acid analog to prevent potential oxidation and peptide
dimerization,37 a modiﬁcation we previously demonstrated
not to aﬀect antigen biology.21 The sequences were elongated
at the N-terminus with either one or six copies of the C-
mannosyl 1, resulting in immobilized peptides 33 and 34
(Scheme 3). Next, 33 and 34 were further extended at their N-
termini with the TLR7 ligand 2-butoxy-8-oxo-adenine, using
the previously described Boc protected building block 32,38 to
give immobilized conjugates 35 and 36. Alternatively, the N-
termini were acetylated, after which the C-termini were further
functionalized by selective removal of the C-terminal lysine
Mmt-group, followed by the introduction of the TLR7 ligand
to provide 37 and 38.39 It was observed that a cocktail of TFA
(1%) in DCM, led to partial removal of the PMB groups
leading to the undesired esteriﬁcation of some of the
carbohydrate alcohols with the TLR7 ligand. Therefore, milder
conditions were explored for the removal of the C-terminal
Mmt group. Eventually, the use of acetic acid in a mixture of
triﬂuoroethanol (TFE) and DCM (1/2/7, v/v/v), a cocktail
ﬁrst described to selectively cleave the Mmt over methyltrityl
and trityl groups selectively,40 was found to be eﬀective for the
selective unmasking of the MMT in the resin-bound protected
conjugates. Using these conditions, the immobilized N-
terminal elongated conjugates 37 and 38 were successfully
generated.
Initial attempts to deprotect and release the peptides from
the resin with a cleavage cocktail of TFA/TIS/H2O (190/5/5,
v/v/v) resulted in complex crude mixtures. Analysis of the
mixtures indicated that the poor quality of the crude material
was due to side reactions of the cleavage and deprotection step
and not due to incomplete couplings. Reactive cationic species
are liberated during the acidic removal of the PMB ethers,
which can react with functional groups in the unprotected
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peptide.41 Howard et al.42 eﬀectively scavenged PMB cations
using phenol as an electron-rich aromatic additive, and when
this additive was applied here, the quality of the crude mixture
indeed improved. Further optimization of the cleavage
conditions was achieved by increasing the concentration of
the scavengers (up to 10% of the total volume) and increasing
the volume of the cleavage medium (eﬀectively diluting the
concentration of reactive cationic species and reactive
functional groups). Using this optimized cleavage protocol,
all four peptides were successfully deprotected and released
from the resin. After RP-HPLC puriﬁcation, the monovalent C-
mannose conjugate 39 was obtained in 2.6% yield after 36
coupling steps and the hexavalent C-mannose conjugate 40 in
1.3% yield over 41 couplings. The conjugates 41 and 42 were
isolated in 2.1% (after 36 steps) and 0.6% (after 41 couplings),
respectively (Scheme 3). Unlike the O-mannoside conjugates
we previously generated, these constructs did not require
additional conjugation and puriﬁcation steps.
Figure 2. Targeting eﬃcacy of the mannoside-peptide conjugates. (A) Schematic representation of the compounds and overview of the moDC
maturation, cytokine secretion, CD4+ and CD8+ T lymphocyte antigen presentation. (B) Expression of costimulatory marker CD86 as measured by
ﬂow cytometry. One out of four donors is depicted. LPS and 49 were included as positive controls, as well as 48 as a negative control. (C) IL-6, IL-
10, IL-12p70, and TNFα secretion of four donors was measured using ELISA upon overnight stimulation with O- or C-mannoside conjugates. (D)
Antigen presentation capacity of moDCs to CD8+ T lymphocytes was quantiﬁed by the IFNγ production of activated T cells. The dashed lines
represent the directionality between the donors when comparing mono- and hexavalent mannosides analogs. (E) Antigen presentation capacity of
moDCs to CD4+ T lymphocytes was quantiﬁed by the IFNγ production of activated T cells.
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To compare the activity of the C- vs the O-mannoside
conjugates, O-mannoside clusters 24 and 27 were function-
alized with an alkyne handle (yielding 43 and 44) and
conjugated through a CuAAC ligation to the TLR7L- gp100
peptide 45 to obtain analogs 46 and 47.
Mannosylated gp100 Conjugate Eﬃcacy As Vacci-
nation Strategy. We analyzed the inﬂuence of the C-
mannosylated antigens on dendritic cell maturation, cytokine
secretion, and antigen presentation to CD4+ and CD8+ T
lymphocytes in relation to their O-mannosylated peptide
counterpart (Figure 2A). Furthermore, the eﬀect of C versus N
terminal ligation of the TLR7 ligand was assessed.
Dendritic cell maturation is considered an essential require-
ment for proper T lymphocyte activation and polarization. As a
measure of DC maturation, we quantiﬁed expression of the
costimulatory molecules CD86 (Figure 2B) and CD83 (see SI,
Figure SI.1D) using the six variants of the trivalent conjugates.
The nonglycosylated gp100 48 and the bivalent gp100-TLR7L
conjugate 49 were included as controls. After overnight
stimulation with the conjugates, we found that all conjugates
induced expression of CD86 and CD83. The C-mannoside
conjugates did not hamper the DC maturation processes and
eﬀectively elevated expression levels to the same extent as the
O-mannosylated conjugates. The position to which the TLR7
agonist was attached does not seem to aﬀect the maturation of
the DCs in this assay.
During maturation, DCs produce and secrete a tailored
cytokine cocktail for subsequent T lymphocyte skewing. The
secreted cytokine proﬁle depends on the triggered TLR, the
signaling pathway of which can be modiﬁed by DC-SIGN or
other CLR engagement.43 To assess DC activation, we
quantiﬁed four key cytokines using a sandwich ELISA. IL-6
and IL-12 are primarily characterized as pro-inﬂammatory
cytokines, with functions aiding DC maturation and Th1
stimulation, respectively. Tumor necrosis factor (TNF)-α is
required for DC activation and proliferation and reduces IL-10
mediated inhibition during DC development.44 IL-10 is a
cytokine that interferes with DC maturation and inhibits the
production of IL-12 and, as such, has been implied to play a
role in skewing of naiv̈e T lymphocytes to Treg diﬀer-
entiation.45 Low levels of autocrine IL-10 prevent spontaneous
maturation of DCs.46 Figure 2C shows that the stand-alone
peptide (48) and gp100-TLR7L (49) minimally induced the
production of IL-6, while both the monovalent and hexavalent
O-mannoside trifunctional conjugates 46 and 47 increased the
secretion of this pro-inﬂammatory cytokine. The monovalent
and hexavalent C-mannoside conjugates 41 and 42 increased
the IL-6 levels to a similar extent as their O-mannoside
counterparts. However, when moDCs were stimulated with
conjugates 39 and 40, having both the C-mannosides and the
TLR7L attached to the N-terminus of the peptide sequence,
cytokine production was abrogated. A similar pattern was
observed for the IL-12 production proﬁle: the O- and C-
mannose conjugates having the TLR7 ligand at the C-terminus
of the conjugate were most active in stimulating the
production of this cytokine, while the gp100 peptide and
gp100 peptide-TLR7L conjugate were less active. The
conjugates 39 and 40 induced low levels of the IL-12 cytokine.
TNF-α expression levels were minimally aﬀected upon
stimulation of the DCs with the various conjugates. Also
here, the conjugates carrying the TLR7 ligand and the
mannosides on the same side of the peptide antigen showed
the least activation. Finally, a low level of the anti-inﬂammatory
IL-10 was detected in the ELISA with the nonstimulated DCs,
as well as for those treated with peptide 49. Figure 2C shows
that while LPS eﬀectively triggers the production of IL-10, the
mannosylated conjugates do not induce the production of this
cytokine. Overall the cytokine production proﬁles of the O-
and C-mannose conjugates appear to be very similar for both
the monovalent and hexavalent clusters. In addition, these
experiments revealed that the arrangement of the CLR and
TLR ligands within the trifunctional conjugates has a great
inﬂuence on the activity of the conjugates. Possibly, the
processing of these conjugates is diﬀerent from the conjugates
bearing the CLR and TLR ligand on either side of the
conjugate, due to diﬀerential cleavage of the conjugates by
proteases.
Finally, we studied the antigen presentation capacity of the
DCs upon stimulation with all the trifunctional conjugate
variations. During DC maturation, the intrinsic focus of these
cells shifts from antigen endocytosis to antigen processing,
major histocompatibility complex (MHC) molecule loading,
and presentation of the antigens for initiation of the T cell
response. Upon recognition of the cross-presented antigen in
MHC-I, cytotoxic CD8+ T cells induce programmed cell death
of targeted cells. On the other hand, CD4+ T lymphocytes
induce and support a cellular and humoral response upon
antigen-MHC-II binding. As both T-cell responses are needed
for a robust immune response, we studied the antigen (gp100)
presenting capacity of the DCs to both CD8+ and CD4+ T cells
after stimulation with the trifunctional conjugates.47 To this
end, DCs were stimulated for 30 min with the conjugates,
before washing and coculturing with the CD8+ HLA-A2.1 or
CD4+ HLA-DR4.1 restricted T cell clone for 24 h. Activation
of T cells was measured by quantiﬁcation of the IFNγ cytokine
produced. As shown in Figure 2D, the conjugates carrying a
TLR7 ligand are more active than the stand-alone peptide,
except for conjugate 40. The introduction of a CLR ligand also
increases the antigen-presenting activity of the conjugates,
although the hexavalent C-mannoside conjugate appears to
hamper antigen presentation with respect to the monovalent
conjugate partially. The presence of the TLR7 ligand and the
hexavalent mannoside cluster on the same side of the
conjugate blocks CD8+ antigen presentation, likely as the
result of suboptimal processing. In our previous study, in which
we have investigated gp100 conjugates bearing hexavalent
clusters comprising di- and trimannosides, we found that the
α1,2-dimannoside cluster gp100 conjugates, although being
the best DC-SIGN binders, showed less antigen presentation
than a gp100-TLR7 conjugate lacking the carbohydrate cluster.
Clusters composed of α1,3- and α1,6-linked dimannosides or
α1,3-α1,6-linked trimannosides showed slightly enhanced
antigen presentation. Taken together, these results show that
optimal antigen presentation requires not only DC-SIGN
binding but also adequate processing of the incorporated
antigens. These results were substantiated by the CD4+ T cell
activation assay, as similar gp100 antigen presentation eﬀects
were seen (Figure 2E). Monovalent O- and C-mannosyl
conjugates 46 and 41 improved antigen presentation to CD4+
T cells most, and attachment of the TLR7 ligand to the same
side as the CLR ligand again nulliﬁed activity of the conjugates.
Overall, also in these assays, the O- and C-mannosides perform
similarly. The combined results from the assays in Figure 2
show that the most attractive vaccine conjugates require the
antigenic peptide to be placed between an N-terminal CLR
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ligand and a C-terminal TLR-ligand for antigen presentation
and secretion cell activation.
■ CONCLUSION
In conclusion, we have developed a C-mannosyl lysine that can
be eﬀectively used in solid-phase peptide synthesis (SPPS)
campaigns. The stability of the C-glycosidic linkage renders the
mannoside stable to both acidic reaction conditions employed
during SPPS and enzymatic degradation. The protecting
groups on the building block were designed to be compatible
with standard SPPS protocols to allow the straightforward “in-
line” incorporation of the mannosylated residues in oligopep-
tides. This allows for the generation of mannosylated
conjugates without the necessity of a postassembly conjugation
step requiring orthogonal click strategies. Not only does this
streamline the synthesis of these conjugates, it also ensures that
bio-orthogonal handles, such as azides and alkynes, can be
incorporated into these multifunctional antigen conjugates to
allow these for the incorporation of additional functionalities,
such as other immune stimulating agents or ﬂuorophores. We
have applied the mannosylated lysine in the assembly of a set
of synthetic long peptide antigens to equip these with either
one or six mannosides to target the antigens to mannose-
binding C-type lectins on professional antigen-presenting cells
to improve the antigenicity of the peptides. The conjugates
were further armed with a synthetic TLR7 ligand to further
boost the response against the antigens. In comparing the C- vs
the O-mannosylated conjugates for DC-SIGN mediated
uptake, DC maturation, and stimulation as well as CD4+ and
CD8+ antigen presentation, the stabilized mannosides
performed virtually identically to their natural analogs. The
conjugates bearing the mannosides and a TLR7 ligand were
shown to bind DC-SIGN and activate DCs, as indicated by
pro-inﬂammatory cytokine release, upregulation of cell surface
maturation markers, and increased antigen presentation to
both CD4+ and CD8+ lymphocytes. Notably, the relative
position of the CLR and TLR ligands in the peptide antigen
conjugates played an important role in shaping the activity of
the conjugates. The conjugates bearing the mannose cluster
and the TLR7 ligand on the same side of the conjugates
proved to be poor immune-stimulating agents, incapable of
elucidating an eﬀective pro-inﬂammatory response and
showing poor antigen presentation. These diﬀerences are
likely due to diﬀerences in the processing of the conjugates. As
DC vaccination therapies hold great promise as an
immunotherapeutic approach to ﬁght cancer, the development
of more eﬀective, tailor-made cancer vaccine conjugates, of
which the action is well understood and can be controlled, is of
great importance. The conjugates described here can be further
equipped with biorthogonal visualization handles to allow
tracking of the conjugates during uptake and processing.
Because the C-mannosyl lysine building block can be
incorporated in an “in-line” manner and does not rely on a
postassembly conjugation step, often used biorthogonal
coupling partners, such as azides and alkynes, remain at
one’s disposal for inclusion in the conjugates.
■ METHODS
Synthesis. The synthesis of C-mannosyl 1 and all clusters and
conjugates is described in the Supporting Information.
Cell Isolation and Culture. Buﬀy coats of healthy donors were
obtained from Sanquin Amsterdam (reference: S03.0023-XT).
Monocytes were isolated using a Ficoll (STEMCELL Technologies)
and sequential Percoll (Sigma) gradient centrifugation. The
monocytes were diﬀerentiated to monocyte-derived dendritic cells
(moDCs) in RPMI 1640 (Invitrogen), supplemented with 10% FCS
(Biowittaker), 1.000 U/mL penicillin (Lonza), 1 U/mL streptomycin
(Lonza), 262.5 U/mL IL-4 (Biosource), and 112.5 U/mL GM-CSF
(Biosource), for 5 days. Flow cytometric monitoring of DC-SIGN
(AZN-D1-Alexa488, in house48), CD83, and CD86 (both PE-
conjugated, Becton Dickinson) expression was conducted for every
donor.
Binding of the Mannose Clusters to moDCs. Day 5 moDCs
(approximately 105 per condition) were washed and resuspended in
ice-cold RPMI medium (Invitrogen). The entire experiment was
conducted at 4 °C with precooled reagents. DC-SIGN and mannose
receptor were blocked with 20 μg/mL AZN-D1 (in house48) and
puriﬁed mouse antihuman CD206 antibody (Clone 19.2, BD
Bioscience), respectively, for 45 min. The biotinylated mannoside
clusters (10 μM) or LewisY-conjugated polyacrylamide (1 μg/mL) as
positive control was allowed to bind for 30 min. The moDCs were
washed with PBS and stained with an Alexa647-labeled streptavidin
(Invitrogen) in PBS supplemented with 0.5% BSA and 0.02% NaN3
(PBA) for 30 min. The moDCs were subsequently washed and ﬁxed
in PBS with 0.5% PFA, before the ﬂuorescence was measured by ﬂow
cytometry (CyAn ADP with Summit Software) and analyzed using
FlowJo v10.
Internalization of the Mannoside Clusters. Day 5 moDCs
(approximately 105 per condition) were washed and resuspended in
ice-cold HBSS medium (Thermo Fischer). The biotinylated manno-
side clusters (20 μM) were added in ice-cold medium to the moDCs
for 1 h and washed away with ice-cold medium. Prewarmed HBSS
(37 °C) was added to the cells and was incubated at 37 °C in a
shaking heating block (800 rpm). Samples of the cells were taken at
the indicated time points (t = 0, 5, 10, 15, 30, 60 min) and
immediately put on ice. The moDCs were washed with ice-cold PBS
supplemented with 0.5% BSA and 0.02% NaN3 (PBA) and stained
with Alexa647-labeled streptavidin (InvitrogenTM) for 30 min at 4
°C. The ﬂuorescence was measured by ﬂow cytometry (CyAn ADP
with Summit Software) and analyzed using FlowJo v10.
Endosomal Routing of the Mannoside Clusters. Day 5
moDCs (approximately 105 per condition) were washed and
resuspended in prewarmed (37 °C) HBSS medium (Thermo
Fischer). The biotinylated mannoside clusters (20 μM) were
complexed with pHrodo (2:1 ratio) for 15 min at RT. The
precomplexed pHrodo-labeled ligands were added to the cells and
were incubated at 37 °C in a shaking heating block (800 rpm).
Samples of the cells were taken at the indicated time points (t = 0, 5,
10, 15, 30, 60, 120 min) and immediately put on ice. The moDCs
were washed with ice-cold PBS supplemented with 0.5% BSA and
0.02% NaN3 (PBA). The ﬂuorescence was measured by ﬂow
cytometry (BD LSRFortessa X-20 with FACSDiva Software) and
analyzed using FlowJo v10.
moDC Cytokine Secretion upon Stimulation with the
Mannoside Clusters. Day 5 moDCs (approximately 50 × 105 per
condition) were stimulated for 24 h with the trifunctional conjugates.
Cytokines IL-6, IL-10, IL-12p40, and TNFα in the supernatant were
measured by sandwich ELISA according to manufacturer’s protocol
(Biosource). The capture antibody was coated in NUNC MaxiSorp
plates (Nunc, Roskilde, Denmark) overnight at 4 °C in PBA-0.05%
BSA. The plates were blocked for 30 min at 37 °C, using PBS
supplemented with 1% BSA. Samples were added for 2 h at RT to
allow binding and subsequently washed, and cytokine levels were
detected using a peroxidase-conjugated cytokine-speciﬁc detection
antibody. After extensive washing, the binding was visualized with
3,3′,5,5′-tetramethylbenzidine (Sigma-Aldrich) and measured by
spectrophotometry at 450 nm on the iMark Microplate Absorbance
Reader (Bio-RAD).
CD4+ and CD8+ Antigen Presentation. Day 5 moDCs of HLA-
A2 and HLA-DR4 double positive donors (approximately 40 × 103
per condition) were incubated with the diﬀerent trifunctional
conjugates (20 μM) for 30 min at 37 °C. A short gp100 peptide
(gp100280−288) and a long gp100 peptide (gp100280−288,40−59) were
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used as controls. The moDCs were washed and separated into two
plates (30 × 103 for CD8+ and 10 × 103 for CD4+ T lymphocyte
coculture). Either a CD8+ HLA-A2.1 restricted T cell clone
transduced with the TCR speciﬁc for the gp100280−288 peptide
49
(approximately 105 cells per condition, E/T ratio 1:3) or a CD4+
HLA-DR4.1 restricted T cell clone transduced with the TCR speciﬁc
for the gp10044−59 peptide (approximately 10
5 cells per condition, E/
T ratio 1:10) was added for overnight coculture. The interferon γ
cytokine secretion was measured by sandwich ELISA, according to
the manufacturer’s protocol (Biosource), and measured by
spectrophotometric analysis at 450 nm on the iMark Microplate
Absorbance Reader (Bio-RAD).
Statistics. Unless otherwise stated, data are presented as the mean
± SD of at least three independent experiments or healthy donors.
Statistical analyses were performed in GraphPad Prism v7.04.
Statistical signiﬁcance was set at P < 0.05, and it was evaluated by
the Mann−Whitney U test.
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(19) Ahleń, G., Strindelius, L., Johansson, T., Nilsson, A.,
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